ARA290 Attenuates Apical Periodontitis via SIRT1/NF-κB/IL-1β Pathway Modulation.

Wang Y, Tang Y, Wang M, Li W, Mu W, Seyam A, Dai Y, Hou T, Guan X

International dental journal17 Jul 2025Cited by 3 (Europe PMC)

PMID40680515PMCIDPMC12284781DOI10.1016/j.identj.2025.100863PepBankPUB-40680515

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In a mouse model of apical periodontitis, ARA290 significantly reduced inflammatory infiltration in the periapical region.
In plain wordsIn mice with apical periodontitis, ARA290 reduced inflammatory cell build-up around the tooth root.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseInflammatory infiltration in periapical region
Study
mousen: not reported in source
Apical periodontitis mouse model
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Additionally, the administration of ARA290 in the AP mouse model significantly reduced inflammatory infiltration, the number of osteoclasts and the extent of bone loss in the periapical region.
1 context sentence(design, population, supporting numbers)
Summary · context
Furthermore, the expression levels of the SIRT1/NF-κB/IL-1β signalling pathway in ARA290-treated AP models, both in vivo and in vitro, were evaluated using immunohistochemistry (IHC), Western blotting, and immunofluorescence (IF) techniques to elucidate the role of ARA290 in modulating this signalli…
Report a problemFND-4068051501
02AnimalAnimal study (in vivo)Efficacy outcome
In a mouse model of apical periodontitis, ARA290 significantly reduced the number of osteoclasts in the periapical region.
In plain wordsIn mice with apical periodontitis, ARA290 reduced the number of bone-resorbing cells near the tooth root.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseOsteoclast number in periapical region
Study
mousen: not reported in source
Apical periodontitis mouse model
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Additionally, the administration of ARA290 in the AP mouse model significantly reduced inflammatory infiltration, the number of osteoclasts and the extent of bone loss in the periapical region.
1 context sentence(design, population, supporting numbers)
Summary · context
Furthermore, the expression levels of the SIRT1/NF-κB/IL-1β signalling pathway in ARA290-treated AP models, both in vivo and in vitro, were evaluated using immunohistochemistry (IHC), Western blotting, and immunofluorescence (IF) techniques to elucidate the role of ARA290 in modulating this signalli…
Report a problemFND-4068051502
03AnimalAnimal study (in vivo)Efficacy outcome
In a mouse model of apical periodontitis, ARA290 significantly reduced the extent of bone loss in the periapical region.
In plain wordsIn mice with apical periodontitis, ARA290 reduced bone loss near the tooth root.
Peptide
Cibinetide (ARA-290)
Outcome
DecreasePeriapical bone loss
Study
mousen: not reported in source
Apical periodontitis mouse model
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Additionally, the administration of ARA290 in the AP mouse model significantly reduced inflammatory infiltration, the number of osteoclasts and the extent of bone loss in the periapical region.
1 context sentence(design, population, supporting numbers)
Summary · context
Furthermore, the expression levels of the SIRT1/NF-κB/IL-1β signalling pathway in ARA290-treated AP models, both in vivo and in vitro, were evaluated using immunohistochemistry (IHC), Western blotting, and immunofluorescence (IF) techniques to elucidate the role of ARA290 in modulating this signalli…
Report a problemFND-4068051503
04AnimalAnimal study (in vivo)Mechanism
In mouse apical periodontitis models, ARA290 treatment increased SIRT1 expression by approximately 40%.
In plain wordsIn mice with apical periodontitis, ARA290 raised levels of the protective protein SIRT1.
Peptide
Cibinetide (ARA-290)
Outcome
IncreaseSIRT1 expression (in vivo)
Study
mousen: not reported in source
Apical periodontitis mouse model
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Measurements
SIRT1 expression increase
≈ 40%
ARA290-treated AP models
Source sentences
Summary
Notably, ARA290 treatment enhanced SIRT1 expression by approximately 40% while concurrently decreasing the levels of acetylated NF-κB (p65) by around 75% and IL-1β by approximately 62.5% in both in vivo and in vitro AP models.
1 context sentence(design, population, supporting numbers)
Summary · context
Furthermore, the expression levels of the SIRT1/NF-κB/IL-1β signalling pathway in ARA290-treated AP models, both in vivo and in vitro, were evaluated using immunohistochemistry (IHC), Western blotting, and immunofluorescence (IF) techniques to elucidate the role of ARA290 in modulating this signalli…
Report a problemFND-4068051504
05AnimalAnimal study (in vivo)Mechanism
In mouse apical periodontitis models, ARA290 treatment decreased acetylated NF-κB (p65) by around 75%.
In plain wordsIn mice with apical periodontitis, ARA290 lowered levels of the inflammation-linked protein acetylated NF-κB.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseAcetylated NF-κB (p65) level (in vivo)
Study
mousen: not reported in source
Apical periodontitis mouse model
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Measurements
Acetylated NF-κB (p65) decrease
≈ 75%
ARA290-treated AP models
Source sentences
Summary
Notably, ARA290 treatment enhanced SIRT1 expression by approximately 40% while concurrently decreasing the levels of acetylated NF-κB (p65) by around 75% and IL-1β by approximately 62.5% in both in vivo and in vitro AP models.
1 context sentence(design, population, supporting numbers)
Summary · context
Furthermore, the expression levels of the SIRT1/NF-κB/IL-1β signalling pathway in ARA290-treated AP models, both in vivo and in vitro, were evaluated using immunohistochemistry (IHC), Western blotting, and immunofluorescence (IF) techniques to elucidate the role of ARA290 in modulating this signalli…
Report a problemFND-4068051505
06AnimalAnimal study (in vivo)Mechanism
In mouse apical periodontitis models, ARA290 treatment decreased IL-1β by approximately 62.5%.
In plain wordsIn mice with apical periodontitis, ARA290 lowered levels of the inflammatory signal IL-1β.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseIL-1β level (in vivo)
Study
mousen: not reported in source
Apical periodontitis mouse model
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Measurements
IL-1β decrease
≈ 62.5%
ARA290-treated AP models
Source sentences
Summary
Notably, ARA290 treatment enhanced SIRT1 expression by approximately 40% while concurrently decreasing the levels of acetylated NF-κB (p65) by around 75% and IL-1β by approximately 62.5% in both in vivo and in vitro AP models.
1 context sentence(design, population, supporting numbers)
Summary · context
Furthermore, the expression levels of the SIRT1/NF-κB/IL-1β signalling pathway in ARA290-treated AP models, both in vivo and in vitro, were evaluated using immunohistochemistry (IHC), Western blotting, and immunofluorescence (IF) techniques to elucidate the role of ARA290 in modulating this signalli…
Report a problemFND-4068051506
07AnimalAnimal study (in vivo)Mechanism
In apical periodontitis models, inhibiting the SIRT1/NF-κB/IL-1β pathway negated the beneficial effects of ARA290.
In plain wordsIn mice with apical periodontitis, blocking the SIRT1 pathway removed the benefit of ARA290.
Peptide
Cibinetide (ARA-290)
Outcome
Not applicableEffect of SIRT1/NF-κB/IL-1β pathway inhibition on ARA290 benefit
Study
mousen: not reported in source
Apical periodontitis mouse model
Outcome group
Receptor activity and mechanism · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Importantly, inhibition of the SIRT1/NF-κB/IL-1β signalling pathway negated the beneficial effects of ARA290 in attenuating the progression of AP.
2 context sentences(design, population, supporting numbers)
Summary · context
Subsequently, the SIRT1/NF-κB/IL-1β signalling pathway was inhibited using selisistat, and the resultant changes in inflammatory levels and bone resorption in periapical lesions were assessed through haematoxylin and eosin staining, tartrate-resistant acid phosphatase staining, IHC and micro-compute…
Summary · context
Furthermore, the expression levels of the SIRT1/NF-κB/IL-1β signalling pathway in ARA290-treated AP models, both in vivo and in vitro, were evaluated using immunohistochemistry (IHC), Western blotting, and immunofluorescence (IF) techniques to elucidate the role of ARA290 in modulating this signalli…
Report a problemFND-4068051510
08LabIn vitro (cells)Mechanism
In an in vitro apical periodontitis model, ARA290 treatment increased SIRT1 expression by approximately 40%.
In plain wordsIn lab tests of an apical periodontitis model, ARA290 raised levels of the protein SIRT1.
Peptide
Cibinetide (ARA-290)
Outcome
IncreaseSIRT1 expression (in vitro)
Study
n: not reported in source
In vitro apical periodontitis model
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Measurements
SIRT1 expression increase
≈ 40%
ARA290-treated AP models
Source sentences
Summary
Notably, ARA290 treatment enhanced SIRT1 expression by approximately 40% while concurrently decreasing the levels of acetylated NF-κB (p65) by around 75% and IL-1β by approximately 62.5% in both in vivo and in vitro AP models.
1 context sentence(design, population, supporting numbers)
Summary · context
Furthermore, the expression levels of the SIRT1/NF-κB/IL-1β signalling pathway in ARA290-treated AP models, both in vivo and in vitro, were evaluated using immunohistochemistry (IHC), Western blotting, and immunofluorescence (IF) techniques to elucidate the role of ARA290 in modulating this signalli…
Report a problemFND-4068051507
09LabIn vitro (cells)Mechanism
In an in vitro apical periodontitis model, ARA290 treatment decreased acetylated NF-κB (p65) by around 75%.
In plain wordsIn lab tests of an apical periodontitis model, ARA290 lowered levels of acetylated NF-κB.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseAcetylated NF-κB (p65) level (in vitro)
Study
n: not reported in source
In vitro apical periodontitis model
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Measurements
Acetylated NF-κB (p65) decrease
≈ 75%
ARA290-treated AP models
Source sentences
Summary
Notably, ARA290 treatment enhanced SIRT1 expression by approximately 40% while concurrently decreasing the levels of acetylated NF-κB (p65) by around 75% and IL-1β by approximately 62.5% in both in vivo and in vitro AP models.
1 context sentence(design, population, supporting numbers)
Summary · context
Furthermore, the expression levels of the SIRT1/NF-κB/IL-1β signalling pathway in ARA290-treated AP models, both in vivo and in vitro, were evaluated using immunohistochemistry (IHC), Western blotting, and immunofluorescence (IF) techniques to elucidate the role of ARA290 in modulating this signalli…
Report a problemFND-4068051508
10LabIn vitro (cells)Mechanism
In an in vitro apical periodontitis model, ARA290 treatment decreased IL-1β by approximately 62.5%.
In plain wordsIn lab tests of an apical periodontitis model, ARA290 lowered levels of IL-1β.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseIL-1β level (in vitro)
Study
n: not reported in source
In vitro apical periodontitis model
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Measurements
IL-1β decrease
≈ 62.5%
ARA290-treated AP models
Source sentences
Summary
Notably, ARA290 treatment enhanced SIRT1 expression by approximately 40% while concurrently decreasing the levels of acetylated NF-κB (p65) by around 75% and IL-1β by approximately 62.5% in both in vivo and in vitro AP models.
1 context sentence(design, population, supporting numbers)
Summary · context
Furthermore, the expression levels of the SIRT1/NF-κB/IL-1β signalling pathway in ARA290-treated AP models, both in vivo and in vitro, were evaluated using immunohistochemistry (IHC), Western blotting, and immunofluorescence (IF) techniques to elucidate the role of ARA290 in modulating this signalli…
Report a problemFND-4068051509

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.